PDCD1 and hepatocellular carcinoma: More recently, immune checkpoint inhibitors (ICI) that target the programmed cell death-1 (PD-1) pathway have emerged as the mainstream option for advanced HCC combination therapy, considering their favorable safety profile and promising objective response (13).